Ozempic, Zepbound, Wegovy, and other GLP-1 medications have transformed the way we lose weight. People who take them report life-changi ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

Drugs like Ozempic and Wegovy are now costing Connecticut taxpayers about $60 million this year and that figure could rise ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

Metformin, an oral medication used to treat type 2 diabetes, is often prescribed off-label for weight loss. It helps to ...

Ozempic, Wegovy or Mounjaro? The battle of the weight-loss injections - As drugs emerge as vital to the Government’s ...

We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.

An estimated 3.4 million Brits meet the criteria to receive a prescription for Wegovy and Mounjaro which would cost ...

A person with a BMI over 35 and those who would like to lose more than 20 pounds is the ideal non-diabetic candidates for GLP ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss management program.